Evidence map›Paper›PMID 25854460›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015

[JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm].

Yuquan Liu, Chuanfang Liu, Na He, Min Wang, Xinxiu Zhang, Dongyi Tang, Chunyan Ji, Daoxin Ma

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Frequency and characteristics of theThe Journal of international medical research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yuquan LiuDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Chuanfang LiuDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Na HeDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Min WangDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Xinxiu ZhangDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Dongyi TangDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Chunyan JiDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Daoxin MaDepartment of Hematology, Qilu Hospital, Shandong University, Ji'nan 250012, China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo detect JAK2 V617F mutation burden and its clinical implications in patients with myeloproliferative neoplasm (MPN).

methodsJAK2 V617F mutation burden were detected by using MGB Taqman probes and its clinical significance were retrospectively studied in 415 MPN patients.

resultsJAK2 V617F was found in 56.9% of all patients [83.5% in polycythemia vera (PV), 55.9% in essential thrombocythemia (ET), 41.9% in primary myelofibrosis (PMF) and 64.7% in MPN-unclassifiable)]. The majority of patients carried heterozygous JAK2 V617F mutation and homozygote was found only in 12 cases (4 in PV, 4 in MPN-U, 2 in PMF, 1 in ET, and 1 in chronic neutrophilic leukemia). Most patients (68.8%) were lower mutation burden (mutation burden<50%), but PV had the highest burden, the moderate burden in PMF and the least in ET. The patient's age and WBC count were significantly correlated with higher mutation burden in PV. WBC count was significantly related to higher mutation burden in ET. WBC count, Hb level and the platelet count were significantly related to higher mutation burden in PMF.

conclusionThe mutation burden of JAK2 V617F from high to low was PV, ET and PMF. The majority of JAK2 V617F mutation was heterozygous. JAK2 V617F mutation burden was positively correlated with age, WBC, Hb and platelet counts.

Indexed as

MutationMyeloproliferative DisordersHomozygoteHumansJanus Kinase 2Leukocyte CountPlatelet CountPolycythemia VeraRetrospective StudiesThrombocythemia, EssentialJAK2 protein, humanJanus Kinase 2

Identifiers

PMID25854460
PMCPMC7342523
OpenAlexW2425925566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.